… (0.48) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
… (0.25) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
… a public offering in October that will allow us to fund operations into 2022, well beyond the expected top-line … of $5.50 per share with full exercise of underwriters’ option to purchase 1,363,636 additional ordinary shares. Net … financial statements, the potential exercise of share options is not included in the diluted earnings per share …
… robust clinical proof of concept in the early phase of our development program. I also want to thank the patients that … LCA10 compound heterozygous patient cells and homozygous optic cups in a dose dependent manner. Based on this data, … into pre-clinical development for the treatment of dystrophic epidermolysis bullosa (DEB). QR-313 is an RNA …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… 10 patients. David M. Rodman, MD was appointed as Chief Development Strategy Officer of ProQR, and will lead the … 10 (LCA 10) patients. The trial, named PQ-110-001, is an open-label trial that will include approximately 6 children … 6 adults (≥ 18 years) that have LCA 10 due to one or two copies of the p.Cys998X mutation. During the trial, patients …
… for QR-110 from the FDA. The planned Phase 1/2 open-label trial (PQ-110-001) will include approximately 6 … 6 adults (≥ 18 years) that have LCA 10 due to one or two copies of the p.Cys998X mutation. During the trial, patients … with expertise in genetic retinal disease in the US and Europe. The primary objective will be to assess safety and …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in